24/7 Market News Snapshot 29 July, 2025 – Cardiff Oncology, Inc. Common Stock (NASDAQ:CRDF)

July 29, 2025

DENVER, Colo., 29 July, 2025 (www.247marketnews.com) – (NASDAQ:CRDF) are discussed in this article.
Cardiff Oncology, Inc. (CRDF) is currently navigating a challenging market landscape, with its stock opening at $3.76 and experiencing a notable decline, now priced at $3.064, representing a decrease of roughly 17.86%. The trading volume reached 6.36 million shares, indicating heightened investor interest which may stem from recent developments and shifting market sentiment. Given this volatility, it is essential for investors to watch technical indicators such as moving averages closely to gauge potential shifts in market trends or continued downside risks. Alongside technical analysis, fundamental evaluations are crucial for painting an accurate picture of the investment outlook.

In parallel, Cardiff Oncology has made significant strides in advancing cancer treatment through its ongoing clinical trials, particularly with the inhibitory potential of Polo-like Kinase 1 (PLK1). The recent appointment of Dr. Roger Sidhu as Chief Medical Officer demonstrates the company’s commitment to bolstering its clinical research efforts. Currently, Cardiff has successfully completed patient enrollment in its Phase 2 CRDF-004 trial, which is investigating the effects of onvansertib in combination with standard therapies for first-line RAS-mutated metastatic colorectal cancer (mCRC). This marks a significant milestone as the company prepares for late-stage clinical development, with findings from this trial expected to play a critical role in future therapeutic approaches.

Additionally, at the American Society of Clinical Oncology (ASCO) Annual Meeting, the company shared encouraging data from an investigator-led trial of onvansertib combined with paclitaxel for metastatic triple-negative breast cancer (mTNBC), reporting a 40% objective response rate. Financially, Cardiff Oncology reported approximately $71.0 million in cash and investments as of June 30, 2025, projecting its financial runway into the first quarter of 2027. With its commitment to innovation and recent strategic initiatives, Cardiff Oncology is well-positioned to address significant unmet needs in the oncology field as it continues to engage with its stakeholders.

Related news for (CRDF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.